Literature DB >> 1933909

Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction.

J Koning1, P Palmer, C R Franks, D E Mulder, J L Speyer, M D Green, K Hellmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1933909     DOI： 10.1016/0305-7372(91)90002-h

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  11 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

2.  Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Bohumir Blazek; Jaroslav Michalek
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

3.  The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.

Authors:  J L Buss; B B Hasinoff
Journal:  Agents Actions       Date:  1993-09

4.  Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Jaroslav Michalek
Journal:  Support Care Cancer       Date:  2005-07-21       Impact factor: 3.603

5.  The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.

Authors:  B B Hasinoff; S V Kala
Journal:  Agents Actions       Date:  1993-05

6.  Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

Authors:  S A van Acker; K Kramer; J A Grimbergen; D J van den Berg; W J van der Vijgh; A Bast
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

Authors:  H Rosing; W W ten Bokkel Huinink; R van Gijn; R F Rombouts; A Bult; J H Beijnen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

10.  A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.

Authors:  M A I Abou-El-Hassan; M J W E Rabelink; W J F van der Vijgh; A Bast; R C Hoeben
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.